Moderator's view: Cyclophosphamide in lupus nephritis

Nephrology Dialysis Transplantation

Volumn 31, Issue 7, 2016, Pages 1058-1061

  Tesar, Vladimir ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

cyclophosphamide; lupus nephritis; mycophenolate; treatment

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE;

CLINICAL PROTOCOL; HUMAN; LUPUS NEPHRITIS; PATIENT COMPLIANCE; REMISSION; STANDARDS;

ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL PROTOCOLS; CYCLOPHOSPHAMIDE; HUMANS; LUPUS NEPHRITIS; PATIENT COMPLIANCE; REMISSION INDUCTION;

EID: 85020545914     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw067     Document Type: Article

References (30)

1. Wilhelmus S, Bajema IM, Bertsias GK et al. Lupus nephrits management guidelines compared. Nephrol Dial Transplant 2016; 31: 904-913
2. Mok CC, YapDY, Navarra SVet al. Overview of lupus nephritismanagement guidelines and perspective from Asia. Nephrology (Carlton) 2014; 19: 11-20
3. Hogan J, Schwenk MH, Radhakrishnan J. Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?. Kidney Int 2012; 82: 1256-1260
4. Muangchan C, van Vollenhoven RF, Bernatsky SR et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2015; 67: 1237-1245
5. Henderson LK, Masson P, Craig JC et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61: 74-87
6. Rovin BH, Parikh SV, Hebert LA et al. Lupus nephritis: induction therapy in severe lupus nephritis: should MMF be considered the drug of choice?. Clin J Am Soc Nephrol 2013; 8: 147-153
7. ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 2014; 66: 3096-3104
8. Wofsy D, Diamond B, Houssiau FA. Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America. Arthritis Rheum 2015; 67: 1144-1146
9. Rathi M, Goyal A, Jaryal A. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int 2016; 89: 235-242
10. Houssiau FA. Moving East: the Euro-Lupus Nephritis regiment in Asia. Kidney Int 2016; 89: 25-27
11. Isenberg D, Appel GB, Contreras G et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010; 49: 128-140
12. Walsh M, Solomons N, Lisk L et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis 2013; 61: 710-715
13. Boneparth A, Ilowite NT. Comparison of renal response parameters for juvenile membranous plus proliferative lupus nephritis versus isolated proliferative lupus nephritis: a cross-sectional analysis of the CARRA Registry. Lupus 2014; 23: 898-904
14. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012; 64: 3660-3665
15. Bose B, Silverman ED, Bargman JM. Ten common mistakes in the management of lupus nephritis. Am J Kidney Dis 2014; 63: 667-676
16. Stoenoiu MS, Aydin S, Tektonidou M. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrol Dial Transplant 2012; 27: 1924-1930
17. Rovin BH, McKinley AM, Birmingham DJ. Can we pesonalize treatment for kidney diseases?. Clin J Am Soc Nephrol 2009; 4: 1670-1676
18. Monroy Trujillo JM, Fine DM. Lupus nephritis in the era of biomarkers. Clin J Am Soc Nephrol 2016; 11: 4-5
19. Hogan J, Avasare R, Radhakrishnan J. Is newer safer?. Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis. Clin J Am Soc Nephrol 2014; 5: 1657-1667
20. Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 2015; 11: 46-61
21. Mejía-Vilet JM, Córdova-Sánchez BM, Arreola-Guerra JM et al. Renal flare prediction and prognosis in lupus nephritis Hispanic patients. Lupus 2016; 25: 315-324
22. Leone A, Sciascia S, Kamal A et al. Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol 2015; 11: 109-116
23. Götestam Skorpen C, Hoeltzenbein M, Tincani A et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016 Feb 17. pii: annrheumdis-2015-20840. doi: 10. 1136/annrheumdis-2015-208840 [epub ahead of print]
24. Bernatsky S, Ramsey-Goldman R, Labrecque J et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013; 42: 130-135
25. Tsang HH, Trendell-Smith NJ, WuAK et al. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus. Lupus 2010; 19: 330-333
26. Houssiau FA. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther 2012; 14: 202
27. Daleboudt GM, Reinders ME, den Hartigh J et al. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus 2013; 22: 171-179
28. Alexander S, Fleming DH, Mathew BS et al. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. Ther Drug Monit 2014; 36: 423-432
29. Tse KC, Tang CS, Lam MF et al. Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis. J Rheumatol 2009; 36: 76-81
30. Nee R, Rivera I, Little DJ et al. Cost-utility analysis of mycophenolate mofetil versus azathioprine based regiments for maintenance therapy of proliferative lupus nephritis. Int J Nephrol 2015; 2015: 917567. doi: 10. 1155/ 2015/917567 [epub 2015 Oct 27]